Talks
IBS Biomarkers Review Article: Key Takeaway
June 1, 2026
IBS Biomarkers Review Article: Leaky Gut
June 1, 2026
IBS Biomarkers Review Article: Post Infectious IBS
June 1, 2026
IBS Biomarkers Review Article: Breath Testing
June 1, 2026
IBS Biomarkers Review Article: Sucrase Isomaltase Deficiency
June 1, 2026
IBS Biomarkers Review Article: Mechanism Changes Management
June 1, 2026
IBS Biomarkers Review Article: Mast Cell Activation Subgroup
June 1, 2026
IBS Biomarkers Review Article: Phenotypes
June 1, 2026
IBS Biomarkers Review Article: Psychological Burden
June 1, 2026
IBS Biomarkers Review Article: Overview
June 1, 2026
Associations Between Physical Activity and IBS: Clinical Takeaway
May 25, 2026
Associations Between Physical Activity and IBS: Limitations
May 25, 2026
Associations Between Physical Activity and IBS: Improvement Mechanisms
May 25, 2026
Associations Between Physical Activity and IBS: Maximum Heart Rate
May 25, 2026
Associations Between Physical Activity and IBS: Intensity Matters
May 25, 2026
Associations Between Physical Activity and IBS: Sedentary Minutes
May 25, 2026
Associations Between Physical Activity and IBS: Daily Steps
May 25, 2026
Associations Between Physical Activity and IBS: Participant Characteristics
May 25, 2026
Associations Between Physical Activity and IBS: Fitbit Accuracy
May 25, 2026
Associations Between Physical Activity and IBS: Overview
May 25, 2026
The Safety of Pharmacotherapy for IBS: Limitations
April 23, 2026
The Safety of Pharmacotherapy for IBS: Key Takeaways
April 23, 2026
The Safety of Pharmacotherapy for IBS: Individualizing Therapy
April 23, 2026
The Safety of Pharmacotherapy for IBS: Symptom Flip
April 23, 2026
The Safety of Pharmacotherapy for IBS: Tricyclic Antidepressants
April 23, 2026
The Safety of Pharmacotherapy for IBS: IBS-D Results
April 23, 2026
The Safety of Pharmacotherapy for IBS: IBS-C Results
April 23, 2026
The Safety of Pharmacotherapy for IBS: Primary Results
April 23, 2026
The Safety of Pharmacotherapy for IBS: NNH
April 23, 2026
The Safety of Pharmacotherapy for IBS: Overview
April 23, 2026
Carbohydrate Intolerance Study: Clinical Implications
March 14, 2026
Carbohydrate Intolerance Study: Proposed Mechanisms
March 14, 2026
Phase 3 BREAKWATER Study: Clinical Implications
March 14, 2026
Carbohydrate Intolerance Study: Predictors of Intolerance
March 14, 2026
Phase 3 BREAKWATER Study: Safety Profile
March 14, 2026
Phase 3 BREAKWATER Study: Subgroup Analysis
March 14, 2026
Carbohydrate Intolerance Study: Fructose Intolerance Symptom Patterns
March 14, 2026
Phase 3 BREAKWATER Study: Overall Survival
March 14, 2026
Phase 3 BREAKWATER Study: Duration of Response
March 14, 2026
Carbohydrate Intolerance Study: Lactose Intolerance Symptom Patterns
March 14, 2026
Phase 3 BREAKWATER Study: Objective Response Rate
March 14, 2026
Carbohydrate Intolerance Study: Prevalence of Intolerance
March 14, 2026
Phase 3 BREAKWATER Study: Population Characteristics
March 14, 2026
Carbohydrate Intolerance Study: Patient Population
March 14, 2026
Carbohydrate Intolerance Study: Design & Methods
March 14, 2026
Phase 3 BREAKWATER Study: Trial Design & Endpoints
March 14, 2026
Phase 3 BREAKWATER Study: Mechanistic Rationale for Combination Therapy
March 14, 2026
Carbohydrate Intolerance Study: Distinguishing Malabsorption, Maldigestion, & Intolerance
March 14, 2026
Carbohydrate Intolerance Study: Overview
March 14, 2026
Phase 3 BREAKWATER Study: Overview
March 14, 2026
ASPREE Follow-Up: Clinical Takeaways
February 20, 2026
ASPREE Follow-Up: Colorectal Cancer
February 20, 2026
ASPREE Follow-Up: Mechanistic Hypotheses
February 20, 2026
ASPREE Follow-Up: Why This Trial Differs
February 20, 2026
ASPREE Follow-Up: Melanoma Outlier
February 20, 2026
IBS Behavioural Therapies: Key Takeaways
February 20, 2026
IBS Behavioural Therapies: Target Matters More Than Technique
February 20, 2026
ASPREE Follow-Up: Legacy Effect
February 20, 2026
IBS Behavioural Therapies: Quality of Review
February 20, 2026
ASPREE Follow-Up: Signal by Cancer Stage
February 20, 2026
Close button
Why are you reporting this TALK?